Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-label Study of Mongersen (GED-0301) in Active Ulcerative Colitis
2015-003364-36Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2015
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mongersen in autoimmune colitis, sponsored by Celgene Corporation. Primary endpoint: Clinical activity by Mayo score. Started Dec 2015; status: completed.
02
Drugs
mongersen
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2015-003364-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003364-36.